• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Otonomy Inc.

    3/30/23 4:25:51 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OTIC alert in real time by email
    S-8 POS 1 d474350ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on March 30, 2023

    Registration No. 333-263110

    333-253000

    333-236716

    333-230055

    333-223522

    333-216401

    333-209990

    333-202851

    333-198116

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    Post-Effective Amendment No. 1 to Registration Statement No. 333-263110

    Post-Effective Amendment No. 1 to Registration Statement No. 333-253000

    Post-Effective Amendment No. 1 to Registration Statement No. 333-236716

    Post-Effective Amendment No. 1 to Registration Statement No. 333-230055

    Post-Effective Amendment No. 1 to Registration Statement No. 333-223522

    Post-Effective Amendment No. 1 to Registration Statement No. 333-216401

    Post-Effective Amendment No. 1 to Registration Statement No. 333-209990

    Post-Effective Amendment No. 1 to Registration Statement No. 333-202851

    Post-Effective Amendment No. 1 to Registration Statement No. 333-198116

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    OTONOMY, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   26-2590070

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    Address Not Applicable1

    (Address of principal executive offices, including zip code)

    2014 Equity Incentive Plan

    2014 Employee Stock Purchase Plan

    (Full title of the plans)

    Otonomy, Inc.

    c/o Corporation Service Company

    251 Little Falls Drive

    Wilmington, New Castle County, Delaware 19808

    (619) 488-6202

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Jennifer Knapp

    Amanda N. Urquiza

    Wilson Sonsini Goodrich & Rosati, P.C.

    650 Page Mill Road

    Palo Alto, California 94304

    (650) 493-9300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Exchange Act.  ☐

     

     

    1 

    Otonomy, Inc. (the “Company”) terminated its lease agreement for office space. Accordingly, the Company does not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any communication required to be sent to the Company’s principal executive offices may be directed to the Company’s agent for service of process at Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808, or to the email address set forth in the Company’s investor relations website.

     

     

     


    EXPLANATORY NOTE

    As contemplated by the Plan of Liquidation and Dissolution of Otonomy, Inc. (the “Company”), the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective on March 28, 2023 and provides for the voluntary liquidation and dissolution of the Company under the General Corporation Law of the State of Delaware (the “Dissolution”). In connection with the Dissolution, all outstanding equity awards granted under or governed by the Company’s equity incentive plans (collectively, the “Plans”), including the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) and the Company’s 2014 Employee Stock Purchase Plan (the “ESPP”), have been cancelled and each of the Plans has been terminated.

    In accordance with the undertaking in the Registration Statements (as defined below), the Company is hereby filing this Post-Effective Amendment No. 1 to each of the Company’s registration statements on Form S-8 (registration nos. 333-263110, 333-253000, 333-236716, 333-230055, 333-223522, 333-216401, 333-209990, 333-202851 and 333-198116) (collectively, the “Registration Statements”) to terminate the effectiveness of each such Registration Statement and to remove from registration all shares of the Company’s common stock that have not been issued and are not subject to issuance pursuant to outstanding equity awards under the Plans, including 14,940,774 shares of the Company’s common stock that have not been issued and are not subject to issuance pursuant to outstanding equity awards under the 2014 Plan and 3,669,417 shares of the Company’s common stock that have not been issued and are not subject to issuance pursuant to the ESPP.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 30, 2023.

     

    OTONOMY, INC.

    By:   /s/ Paul E. Cayer
      Paul E. Cayer
      President, Secretary and Chief Financial and Business Officer

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements.

    Get the next $OTIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OTIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Hogan H Michael Iii

      3 - OTONOMY, INC. (0001493566) (Issuer)

      2/24/23 4:53:45 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Weber David Allen covered exercise/tax liability with 91,636 shares, decreasing direct ownership by 24% to 285,863 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:31:39 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cayer Paul E covered exercise/tax liability with 40,054 shares, decreasing direct ownership by 18% to 183,733 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:30:19 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care